Abstract:Breast cancer is the most common malignant tumors among women in the worldwide. The status of estrogen receptor in breast cancer is usually associated with prognosis and response to hormonal therapy. estrogen receptor status varies among breast cancers, with one third of the disease showing estrogen receptor negative. Absence of estrogen receptor is known to be associated with poor differentiation of tumor cells, resistance to hormonal therapy, and poor clinical outcome; thus, a better understanding of the causes and mechanisms underlying the loss or reduction of estrogen receptor in breast cancer may help identify novel strategy for treating breast cancer. We recently found that the expression of ubiquitin C terminal hydrolaseL1 (UCHL1), an enzyme that uniquely possesses both ubiquitin hydrolase and ligase activity, is conversely related with estrogen receptor status in breast cancer. UCHL1 is overexpressed in estrogen receptor (-) breast cancer cell lines and tumor samples, but is barely detectable in estrogen receptor (+) breast cancer cell lines and tumor samples. Overexpression of UCHL1 in estrogen receptor (+) cells resulted in a remarkable reduction of estrogen receptor mRNA and protein; however, UCHL1 inhibitor or UCHL1 siRNA upregulated the protein and mRNA levels of estrogen receptor in estrogen receptor (-) cells. We further demonstrated that the regulatory effect of UCHL1 on estrogen receptor resulted from this deubiquitylase-mediated stability of EGFR, which promotes the transcription of estrogen receptor. Inhibition of UCHL1 could significantly enhance the sensitivity of estrogen receptor (-) breast cancer cells to tamoxifen, the most commonly used anti estrogen agent in the treatment of this disease. These data demonstrated that UCHL1 may be a potential molecule target to sensitize hormone resistant human breast cancers to anti estrogen agent. Our findings not only provided a basis for new approaches to upregulating estrogen receptor level, but also present a new rationale strategy for developing more effective therapies for estrogen receptor negative breast cancer, and a new pharmacologic target for drug development.

Inhibition of UCHL1 Enhances the Sensitivity of Estrogen Receptor Negative Breast Cancer Cells to Endocrine Therapy

UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.

UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5

Uch-L1 Involved in Regulating the Degradation of Egfr and Promoting Malignant Properties in Drug-Resistant Breast Cancer

Lower Beclin 1 Downregulates HER2 Expression to Enhance Tamoxifen Sensitivity and Predicts a Favorable Outcome for ER Positive Breast Cancer

UHRF1 Modulates Breast Cancer Cell Growth Via Estrogen Signaling

The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis

Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway.

UBE2M forms a positive feedback loop with estrogen receptor to drive breast cancer progression and drug resistance

UCHL1 is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance

UCHL1 promotes cancer stemness in triple-negative breast cancer

USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα

The Ubiquitin Peptidase Uchl1 Induces G0/G1 Cell Cycle Arrest And Apoptosis Through Stabilizing P53 And Is Frequently Silenced In Breast Cancer

Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer

Over-expression of Ubiquitin Carboxy Terminal Hydrolase-L1 Induces Apoptosis in Breast Cancer Cells.

Epigenetic Identification of Ubiquitin Carboxyl-Terminal Hydrolase L1 As a Functional Tumor Suppressor and Biomarker for Hepatocellular Carcinoma and Other Digestive Tumors

Estrogen Deprivation and Inhibition of Breast Cancer Growth in Vivo Through Activation of the Orphan Nuclear Receptor Liver X Receptor.

Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review).

Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms

The Effects of UCH-L3 on the Biological Behaviours of Breast Cancer: Correlation with the Expressions of HIF-1α

The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.